umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Risk For Low Visual Acuity After 1 And 2 Years Of Treatment With Ranibizumab Or Bevacizumab For Patients With Neovascular Age-Related Macular Degeneration
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Oftalmiatrik.
2017 (Engelska)Ingår i: Retina, ISSN 0275-004X, E-ISSN 1539-2864, Vol. 37, nr 11, s. 2035-2046Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice.

Methods: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years.

Results: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug.

Conclusion: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.

Ort, förlag, år, upplaga, sidor
Lippincott Williams & Wilkins, 2017. Vol. 37, nr 11, s. 2035-2046
Nyckelord [en]
neovascular age-related macular degeneration, bevacizumab, choroidal neovascularization, ETDRS, nibizumab, register data
Nationell ämneskategori
Oftalmologi
Identifikatorer
URN: urn:nbn:se:umu:diva-145623DOI: 10.1097/IAE.0000000000001431ISI: 000425208800022PubMedID: 28141748OAI: oai:DiVA.org:umu-145623DiVA, id: diva2:1190599
Tillgänglig från: 2018-03-15 Skapad: 2018-03-15 Senast uppdaterad: 2018-06-09Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Westborg, IngerRosso, Aldana

Sök vidare i DiVA

Av författaren/redaktören
Westborg, IngerRosso, Aldana
Av organisationen
Oftalmiatrik
I samma tidskrift
Retina
Oftalmologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 72 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf